QURE · uniQure N.V. · Investor Relations

$21.58 -0.13 (-0.58%) Play latest call Q3 2026 earnings call transcript

Market Cap

$1.52B

70.14M

Volume · Nov 9 279.16K Avg daily vol (3M) 2.16M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-11-04	uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
2026-11-02	uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
2026-10-28	uniQure to Announce Third Quarter 2026 Financial Results
2026-09-29	uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

Past events

Date	Event	Type
2026-11-04	uniQure to Announce Third Quarter 2026 Financial Results	Earnings call
2026-09-29	Phase I/II AMT-130 Huntington's Disease Update	Webcast
2026-07-29	Earnings conference call (announced in 8-K)	Earnings call
2026-05-19	2026 RBC Capital Markets Global Healthcare Conference	Conference
2026-05-05	uniQure First Quarter 2026 Earnings Call	Earnings call
2026-03-02	uniQure Fourth Quarter and Year End 2025 Earnings Call	Earnings call
2026-03-02	TD Cowen 46th Annual Health Care Conference	Conference
2025-11-10	uniQure Third Quarter 2025 Earnings Call	Earnings call
2025-09-24	Pivotal Phase I/II AMT-130 Huntington's Disease Update	Webcast
2025-07-29	uniQure Second Quarter 2025 Earnings Call	Earnings call
2025-06-02	Regulatory Update on AMT-130 for Huntington's Disease	Webcast

Source: https://www.uniqure.com/investors-media

Key facts CIK 1590560 CUSIP N90064101 13F (30d) 95 filings 72 filers Visit website Investor relations